Companies Dominating the Stem Cell Treatment Landscape
- Stemedica Cell Technologies, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pluristem Therapeutics Inc.
- Thermo Fisher Scientific
- Becton, Dickinson and Company
- Advanced Cell Technology Inc.
- Cellular Engineering Technologies Inc.
- CellGenix GmbH
- PromoCell GmbH
- Kite Pharma
- Genea Biocells
Browse Key Market Insights with Data Illustration:
In the News
-
A new drug application (IND) has been approved by FDA for Stemedica Cell Technologies, Inc. in order to treat moderate-to-severe COVID-19 with intravenous administration of allogeneic mesenchymal stem cells (MSCs). This new application has shown to be effective in treating the symptoms of moderate-to-severe COVID-19, such as inflammation, fever, and difficulty breathing.
-
An official announcement from Pluristem Therapeutics Inc. announced that the company's subsidiary, Pluristem Ltd., has signed a non-binding Memorandum of Understanding (MOU) with the Abu Dhabi Stem Cells Center (ADSCC), a special healthcare center for cell therapy and regenerative medicine based in the United Arab Emirates.
